Navigation Links
Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
Date:11/26/2008

o be valid and enforceable. The patent position for this product is strong and we intend to vigorously defend the AMRIX intellectual property."

"We believe our Orange Book-listed patent provides coverage for AMRIX until 2025 and we intend to work diligently with Cephalon to protect this important product," said Manya S. Deehr, Eurand's Chief Legal Officer.

The filing of this lawsuit is provided for by the Hatch-Waxman Act, a federal statute governing certain aspects of generic drug approvals. Under that statute, the filing of the lawsuit stays any FDA approval of the Mylan and Barr ANDAs until the earlier of a district court judgment in favor of Mylan or Barr or 30 months from the October 2008 receipt of the Mylan and Barr Paragraph IV certification letters.

Eurand developed AMRIX based on its patented and proprietary drug delivery formulation technologies. Cephalon is the exclusive licensee and marketer of AMRIX in the United States. Concurrent with the patent protection described above, Cephalon has a three-year period of marketing exclusivity preventing FDA approval of a generic version of AMRIX until February 2010.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: TREANDA(R)
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...s Customers with Partners Validated to Process and...ts , Ottawa, ON (PRWEB) N...der of products for biological sample collection, ... new global partner program. The program offers si...ommunity and is designed to help partners scale an...
(Date:11/23/2009)...ovocative new study, a University of Utah scientis... major cause of global warming cannot be stabiliz... builds the equivalent of one new nuclear power pl...ill be any substantial near-term departure from re...ssion rates," says the new paper by Tim Garrett, a...
(Date:11/23/2009)...carbon layer in which the carbon atoms are arrange...Carbon nanotubes are rolled-up sheets of graphene,... Graphene boasts some very special characteristics...rmal conductor, and reconciles such conflicting qu... graphene is impermeable to gases, which makes it ...
(Date:11/23/2009)...irstCall/--NeogenCorporation(Nasdaq: NEOG )announc...en,sBoardofDirectorsatthecompany,srecentannualmeet...ofexperienceinthefood,agriculture,andtradeindustri...uraleconomicsatVirginiaTechUniversity.FromJanuary2...turenegotiatorwiththerankofambassador. ,, "Sinc...
Breaking Biology Technology:DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4Polymer with honeycomb structure 2Richard T. Crowder Joins Neogen's Board of Directors 2
..., Oct. 24 SenesTech, Inc. has initiated,field tri...sland of Java in,continuing research collaboration... Dr. Grant Singleton of the International Rice,Res...ta Mayer and Cheryl,Dyer of SenesTech, Inc. will j...cientific and Industrial Research Organisation (CS...
...t. 24 The Committee for,Medicinal Products for Hu...MEA) has adopted a negative opinion on a Cymbalta(...treatment of fibromyalgia., "Eli Lilly and Compan...ted by the CHMP,s opinion," said James Russell, M....lly and Company. "We remain,confident in the dulox...
...24 Favrille, Inc. (OTC,Bulletin Board: FVRL) anno... term sheet for a reverse merger whereby Favrille ...e company, MyMedicalRecords.com, Inc.,("MMR"), in ...becoming a,wholly-owned subsidiary of Favrille. If...rms set forth in the non-binding term sheet, at th...
Other Biology Technology:SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia 2European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia 2European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia 3European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia 4European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia 5Favrille Announces Execution of Non-binding Term Sheet for a Merger Transaction 2
(Date:11/23/2009)...ire microbiologist Louis Tisa has received two gra...the actinorhizal plants, widespread woody plants w...ated soils. , The United States Department of A...ecular, cellular and biomedical sciences, $399,000... bacteria Frankia and Casuarina, an actinorhizal p...
(Date:11/23/2009)...edical engineer and cardiologist Tzung "John" Hsia...istinguish cardiac emergencies requiring immediate...gs and lifestyle change. , Angiograms, images ma... the heart, offer an inside view of the interior s...ealing deposits of a dangerous fatty substance cal...
(Date:11/23/2009)...sted for 360 million years and survived when the d...tening to make many of them extinct, according to ...Today . , The fungus, Batrachochytrium dendrob...s of amphibian extinctions in Central America and ...over 350 amphibian species by penetrating their sk...
Breaking Biology News(10 mins):UNH prof. receives nearly $500,000 to research environmentally significant plants 2Stable plaque or heart attack plaque? USC researcher builds new sensor to tell which is which 2Keryx Reports Results of Open Label Extension Study Examining Long Term Use of Zerenex an Iron Based Phosphate Binder for the Treatment of Hyperphos 5032 1Keryx Reports Results of Open Label Extension Study Examining Long Term Use of Zerenex an Iron Based Phosphate Binder for the Treatment of Hyperphos 5032 2Keryx Reports Results of Open Label Extension Study Examining Long Term Use of Zerenex an Iron Based Phosphate Binder for the Treatment of Hyperphos 5032 3Keryx Reports Results of Open Label Extension Study Examining Long Term Use of Zerenex an Iron Based Phosphate Binder for the Treatment of Hyperphos 5032 4Discovery could improve hepatitis C treatment 58129 1Discovery could improve hepatitis C treatment 58129 2InVitria Presents Zap CHO Performance Results at PEACe Conference 10054 1InVitria Presents Zap CHO Performance Results at PEACe Conference 10054 2
..., A collaboration between more than 70 researcher... the X chromosome that, when knocked-out, lead to ...ied almost all X chromosome genes in 208 families ... this type ever reported. , Remarkably, the team...omosome genes, when knocked-out, have no apparent ...
..., SALT LAKE CITY As the U.S. Southwest grew war... vanished from what is now the Mojave Desert, robb...ty of Utah biologists have narrowed the hunt for d... creosote bushes that replaced juniper. , "It wa...or Denise Dearing, senior author of the study, pub...
..., , As the U.S. Southwest grew warmer between 18,7...om what is now the Mojave Desert, robbing woodrats...rrowed the hunt for detoxification genes that let ...laced junipers. , "It was either eat it or move o...ty of Utah, lead author of a paper detailing the r...
Other Biology News:The genetic X-factor 2The genetic X-factor 3Poison: It's what's for dinner 2Poison: It's what's for dinner 3Poison: It's what's for dinner 4Poison: It's what's for dinner 5Desert woodrats switch one dietary poison for another 2
...y scanner based on patented confocal laser imaging...patial resolution. The DNAscope LM is unique beca...t is upgradeable to a total of 3 laser excitation ... (computer), monitor, and software easy to use ...
...ures an ultra-thin nitrocellulose coating for mult...rst protein microarray slide to provide the many b...background fluorescence providing excellent signal...ed for a variety of assays, such as sandwich immun...
Conjugate Stabilizing Diluent Alkaline Phosphatase from Meridian Life Science, Inc.
...Alkaline Phosphatase conjugates. The product insu...the enzyme and the antibody following long-term st...emically engineered to increase conjugate stabilit...stance to various shipping conditions and storage ...
Biology Products: